

Almudena Matito

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6963664/publications.pdf>

Version: 2024-02-01

37
papers

1,823
citations

304368

22
h-index

360668

35
g-index

38
all docs

38
docs citations

38
times ranked

1315
citing authors

#	ARTICLE	IF	CITATIONS
1	Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis. <i>Blood</i> , 2022, 139, 572-583.	0.6	8
2	Mastocytosis presenting with mast cell mediator release-associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features. <i>Clinical and Translational Allergy</i> , 2022, 12, e12132.	1.4	11
3	Simultaneous occurrence of cutaneous mastocytosis and juvenile xanthogranuloma in a child: Random or true association?. <i>Pediatric Dermatology</i> , 2020, 37, 716-720.	0.5	0
4	Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 552.	1.8	9
5	Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. <i>Blood</i> , 2019, 134, 456-468.	0.6	44
6	Perioperative anaphylaxis in a patient with a solitary mastocytoma. <i>Pediatric Dermatology</i> , 2019, 36, 352-354.	0.5	4
7	Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 880-893.	1.5	50
8	Cutaneous Mastocytosis With Predominant Infiltration of Promastocytes. <i>American Journal of Dermatopathology</i> , 2019, 41, 296-299.	0.3	1
9	Impact of somatic and germline mutations on the outcome of systemic mastocytosis. <i>Blood Advances</i> , 2018, 2, 2814-2828.	2.5	42
10	Cutaneous Mastocytosis in Adults and Children. <i>Immunology and Allergy Clinics of North America</i> , 2018, 38, 351-363.	0.7	46
11	Bone Marrow Expression of Mast Cell Disorders. <i>Immunology and Allergy Clinics of North America</i> , 2018, 38, 379-395.	0.7	2
12	KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression. <i>Blood</i> , 2016, 127, 761-768.	0.6	33
13	Systemic mastocytosis presenting as occupational IgE-mediated anaphylaxis to pine processionary caterpillar. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 333-334.e1.	0.5	7
14	Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. <i>British Journal of Haematology</i> , 2016, 172, 56-63.	1.2	15
15	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 35-45.	1.5	289
16	Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 168-178.e1.	1.5	72
17	The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. <i>Journal of Leukocyte Biology</i> , 2015, 97, 49-59.	1.5	47
18	Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. <i>Modern Pathology</i> , 2015, 28, 1138-1149.	2.9	88

#	ARTICLE	IF	CITATIONS
19	Systemic mastocytosis presenting as IgE-mediated food-induced anaphylaxis: A report of two cases. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 456-458.	2.0	11
20	Management of Anesthesia in Adult and Pediatric Mastocytosis: A Study of the Spanish Network on Mastocytosis (REMA) Based on 726 Anesthetic Procedures. <i>International Archives of Allergy and Immunology</i> , 2015, 167, 47-56.	0.9	66
21	Response to celecoxib in a patient with indolent systemic mastocytosis presenting with intractable diarrhea. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 115, 456-457.	0.5	3
22	Management of adult mastocytosis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 321-336.	0.5	4
23	Flow Cytometry in Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 297-313.	0.7	14
24	Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 520-528.e5.	1.5	118
25	<scp>CD</scp>30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. <i>Histopathology</i> , 2013, 63, 780-787.	1.6	77
26	Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1213-1224.e4.	1.5	30
27	Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 614-615.	1.5	41
28	Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 111, 425-426.	0.5	33
29	Venom Immunotherapy in Patients with Clonal Mast Cell Disorders: Efficacy, Safety, and Practical Considerations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2013, 1, 474-478.	2.0	85
30	Flow Cytometry Criteria for Systemic Mastocytosis: Bone Marrow Mast Cell Counts Do Not Always Count. <i>American Journal of Clinical Pathology</i> , 2013, 139, 404-406.	0.4	6
31	Serum Tryptase Monitoring in Indolent Systemic Mastocytosis: Association with Disease Features and Patient Outcome. <i>PLoS ONE</i> , 2013, 8, e76116.	1.1	29
32	Complete Response After Imatinib Mesylate Therapy in a Patient With Well-Differentiated Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2012, 30, e126-e129.	0.8	59
33	Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. <i>Modern Pathology</i> , 2012, 25, 516-521.	2.9	55
34	Determinación de triptasa en el líquido de una ampolla en un caso de mastocitosis cutánea eritrodérmica difusa. <i>Revista Del Laboratorio Clínico</i> , 2012, 5, 127-129.	0.1	0
35	Evaluation of the WHO criteria for the classification of patients with mastocytosis. <i>Modern Pathology</i> , 2011, 24, 1157-1168.	2.9	89
36	Dermoscopic Features of Skin Lesions in Patients With Mastocytosis. <i>Archives of Dermatology</i> , 2011, 147, 932.	1.7	72

#	ARTICLE	IF	CITATIONS
37	Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 1269-1278.e2.	1.5	263